Découvrez ici la liste des différentes études cliniques en cours classées par centre.
Etudes sponsorisées interventionnelles en cours:
Etudes sponsorisées non interventionnelles en cours:
Etudes académiques non interventionnelles en cours:
| Etudes Onco en cours | |||
| 1st line | |||
| Acronyme | Studies | Cancer | PI |
| BO29554 study (B-FAST) | A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial) | NSCLC (ROS+) A venir: BRAF V600+ | P.C |
| ADRIATIC (D933QC00001) | Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT) | SCLC limités post-chimioradio | T.P |
| ANAM 17-21 | A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC | NSCLC cachexia | T.P |
| Zenith20 (Spectrum) (SPI-POZ-202) | Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202) | NSCLC IV EGFR ou HER2 exon 20 inser/mut | T.P |
| CA209-73L | A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC) | NSCLC IIIA/B/C | TP |
| 2nd line | |||
| ImmunoSABR | Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer | NSCLC IV | X.G |
| AMG510 (20190009) | A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | NSCLC KRAS p.G12C | ThP |
| ≥ 3rd line | |||
| ImmunoSABR | Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer | NSCLC IV | X.G |
| Autres | |||
| Acronyme | Studies | Cancer | PI |
| EORTC: E2-Radiate 1811 | E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe | Tous cancers oligométa traités par Rth | XG |
| PACIFIC R D4194R00005 | First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy | NSCLC stage III with durvalumab post chimioradio | T.P |
| Immuno Poumon | Etude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumon | NSCLC | FAb |
| SPECTA | Screening Cancer Patients for Efficient Clinical Trial Access | NSCLC IV naïfs/ thymomes, mésothéliome IV naïfs | T.P |
| Category | Sub-category | Name | Eudract | Title | Molecules | PhaseEtude | Status |
| Lung and Thorax | NSCLC | 01151 | Cardiovascular morbidities and lung cancer treatment: a prospective registry | Observationnelle | Open | ||
| Lung and Thorax | NSCLC | PDC-Lung-101 | 2018-002382-19 | An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) | PDC*lung01 | Phase 1a | Open |
| Lung and Thorax | NSCLC | ANAM-17-21 | 2018-002927-40 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC) | Anamorelin HCL | Phase 3 | Open |
| Lung and Thorax | NSCLC | SAPPHIRE | 2019-001043-41 | A randomized phase 3 study of Sitravatinib in combination with Nivolumab versus Docetaxel in patients with advanced non-squamous non-small cell lung cancer with disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy. | Sitravatinib | Phase 3 | Open |
| Lung and Thorax | NSCLC | PACIFIC-4 | 2018-002572-41 | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | Durvalumab | Phase 3 | Open |
| Lung and Thorax | NSCLC | EXCLAIM-2 | 2019-001845-42 | Phase III clinical trial evaluating TAK-788 versus platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) as first-line treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. | TAK-788 | Phase 3 | Open |
| Lung and Thorax | NSCLC | Skyscraper 03 | 2019-0044773-29 | A phase 3, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage 3 non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation. | Tiragolumab | Phase 3 | Open |
| Lung and Thorax | NSCLC | MARIPOSA | 2020-000743-31 | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer – MARIPOSA | Amivantamab (JNJ-61186372) | Phase 3 | Open |
| Lung and Thorax | NSCLC | MK7684A-002 | 2020-004034-38 | A Phase 2, Multi-center, Randomized Study to Compare the Efficacy and Safety of MK-7684A Or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With A Platinum Doublet Chemotherapy and Immunotherapy | MK-7684A | Phase 2 | Open |
| Lung and Thorax | NSCLC | CodeBreaK 100 | 2018-001400-11 | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100) | AMG 510 | Phase 2 | Open |
| All tumors | All tumors | Precision 2 - Afatinib | 2016-003411-34 | Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation followed by the addition of paclitaxel to afatinib at disease progression. | Afatinib | Phase 2 | Open |
| All tumors | All tumors | Precision 2 – Olaparib | 2018-002966-37 | Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. SAUF SEIN, OVAIRE, PROSTATE, ATM gene | Olaparib | Phase 2 | Open |
| All tumors | All tumors | DF1001-001 | 2019-004706-10 | A phase I/II, first-in-human, multi-part, open-label, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expansion in selected indications | DF1001 | Phase 2 | Open |
| All tumors | All tumors | Precision 1 | The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment “PRECISION 1” | Prospective-Collection d'échantillons | Open | ||
| All tumors | All tumors | GeNeo | A study to examine the value of broad agnostic NGS panel testing versus reimbursed organ-directed NGS: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre. | Prospective-Collection d'échantillons | Open | ||
| All tumors | All tumors | TAPISTRY | 2020-001847-16 | Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in patients with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by an next-generation-sequencing (NGS) assay | Phase 2 | Open | |
| All tumors | All tumors | BALLETT | A study to examine the clinical value of comprehensive genomic profiling performed by Belgian NGS laboratories: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre - Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) | Prospective-Collection d'échantillons | Open | ||
| All tumors | All tumors | SGNTUC-019 | A phase 2 basket study of Tucatinib in combination with Trastuzumab in subjects with previously treated, locally advanced unresectable or metastatic solid tumors driven by HER2 alterations | Tucatinib | Phase 2 | Open | |
| All tumors | All tumors | BrainStorm program | A Brain metastases research Platform to tackle the challenge of CNS metastases in solid tumours | Prospective-Collection d'échantillons | Open | ||
| Lung and Thorax | SCLC | MK7339-013 | 2019-003616-31 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) | Pembrolizumab (MK-3475) | Phase 3 | Near future |
| Lung and Thorax | NSCLC | 849-012 (Krystal program) | A randomized Phase 3 study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation | MRTX849 (KRAS G12C inhibitor) | Phase 3 | Near future | |
| Lung and Thorax | SCLC | CA001-050 | A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | BMS-986012 | Phase 2 | Near future |
